- Home
- BLX vs CDTX Comparison
BLX vs CDTX Comparison
Compare BLX & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLX
- CDTX
- Stock Information
- Founded
- BLX 1977
- CDTX 2012
- Country
- BLX Panama
- CDTX United States
- Employees
- BLX N/A
- CDTX N/A
- Industry
- BLX Commercial Banks
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLX Finance
- CDTX Health Care
- Exchange
- BLX Nasdaq
- CDTX Nasdaq
- Market Cap
- BLX 1.7B
- CDTX 1.6B
- IPO Year
- BLX N/A
- CDTX 2015
- Fundamental
- Price
- BLX $47.67
- CDTX $65.62
- Analyst Decision
- BLX
- CDTX Strong Buy
- Analyst Count
- BLX 0
- CDTX 11
- Target Price
- BLX N/A
- CDTX $57.00
- AVG Volume (30 Days)
- BLX 106.5K
- CDTX 468.4K
- Earning Date
- BLX 10-28-2025
- CDTX 11-06-2025
- Dividend Yield
- BLX 5.17%
- CDTX N/A
- EPS Growth
- BLX 12.91
- CDTX N/A
- EPS
- BLX 5.97
- CDTX N/A
- Revenue
- BLX $306,166,000.00
- CDTX N/A
- Revenue This Year
- BLX $15.00
- CDTX N/A
- Revenue Next Year
- BLX $5.52
- CDTX N/A
- P/E Ratio
- BLX $8.09
- CDTX N/A
- Revenue Growth
- BLX 12.96
- CDTX N/A
- 52 Week Low
- BLX $29.95
- CDTX $10.14
- 52 Week High
- BLX $48.38
- CDTX $69.36
- Technical
- Relative Strength Index (RSI)
- BLX 64.89
- CDTX 58.37
- Support Level
- BLX $45.97
- CDTX $61.10
- Resistance Level
- BLX $48.38
- CDTX $65.84
- Average True Range (ATR)
- BLX 0.77
- CDTX 3.06
- MACD
- BLX 0.05
- CDTX -0.42
- Stochastic Oscillator
- BLX 75.77
- CDTX 73.11
About BLX Banco Latinoamericano de Comercio Exterior S.A.
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.